Biomarker of Neuroinflammation in Parkinson’s Disease: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Conner Chen and Version 1 by Tsai Wei Liu.

Parkinson's disease is caused by an abnormal accumulation of alfa-synuclein in dopaminergic neurons of the substantial nigra, which subsequently causes motor symptoms. Neuroinflammation plays a vital role in the pathogenesis of neurodegeneration in PD. This neuroinflammatory neurodegeneration involves the activation of microglia, upregulation of proinflammatory factors, and gut microbiota. In this review, we summarized the recent findings on the detection of PD by using inflammatory biomarkers and radiotracers, as well as by monitoring disease progression and the treatment response. 

  • Parkinson’s disease
  • Neuroinflammation

1. Introduction

Parkinson’s disease (PD) is a common neurodegenerative disease characterized by the loss of dopaminergic (DAergic) neurons in the substantia nigra pars compacta (SNpc). Its main symptoms include resting tremors, rigidity, shuffling gait, and bradykinesia. The pathogenesis of neurodegeneration in PD is driven by the abnormal accumulation of misfolded α-synuclein in the central nervous system (CNS) [1]. The subsequent neurotoxic cascades involving genetic [2[2][3],3], environmental [4], and immunological factors [5] can further enhance the neurotoxicity of misfolded α-synuclein, causing neurodegeneration in the neighboring brain regions. Genome-wide association studies have identified many genetic variants associated with PD. Studies of animal models, neuroimages, and postmortem pathology have also provided substantial insights into the involvement of neuroinflammation in PD pathogenesis [6[6][7][8],7,8], and indicate that cytokine-induced inflammatory responses may play a vital role.
At present, no effective treatment exists to halt PD progression. Sensitive and practical biomarkers of PD are urgently required, and their efficacy for diagnosing PD in early or presymptomatic stages should be validated in clinical trials. Various molecules in the cerebrospinal fluid (CSF), such as α-synuclein, DJ-1, amyloid-β, tau, and lysosomal enzymes, may be biomarkers of PD [9,10][9][10]. Positron emission tomography, single-photon emission computed tomography, and magnetic resonance imaging are important imaging tools that reveal DAergic nerve projections in SN. Recently, studies involving neuroimaging, neuropathology, and cell and animal models further indicated an important interaction between neuroinflammation and neurodegeneration of DAergic neurons in PD [6,7,8][6][7][8].

2. Role of Neuroinflammation in PD

In the early 1980s, McGeer observed activated microglial infiltrations in the SN of the postmortem PD brain [6]. Numerous studies have since been conducted on the neuroinflammation associated with PD pathogenesis, such as increased proinflammatory cytokines in the blood [11] or CSF [10,12][10][12]. Activated microglia secrete several proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, and IL-6 [11,13,14,15,16][11][13][14][15][16]. They also express major histocompatibility complex (MHC) class II, and are associated with damaged neurons in patients with PD [17]. Furthermore, neuroimaging studies have used radiotracers specific to microglial activation to demonstrate ongoing neuroinflammation in PD [18,19][18][19]. A well-known example is [11C](R)PK11195 binding to several brain regions in patients with PD [7]. The aggregation of the abnormal, insoluble form of α-synuclein plays a key role in PD pathogenesis [20]. Misfolded α-synuclein is involved in the pathogen-associated molecular pattern- or damage-associated molecular patterns (DAMP)-mediated dysregulation of microglial toll-like receptor (TLR)2 or TLR4-mediated signaling pathway, which ultimately activates myeloid differentiation primary response 88 (MyD88) and nuclear factor kappa B (NFκB), triggering TNF-α and IL-1β production [21]. The treatment of BV2 mouse microglial cells or primary microglia with aggregated α-synuclein upregulates the production of TNF-α, IL-1β, monocyte chemoattractant protein (MCP)-1, and interferon (IFN)-γ [22,23,24][22][23][24]. Panicker et al. demonstrated that aggregated α-synuclein binds to the microglial surface cell membrane receptors TLR2 and CD36, then recruits Fyn kinase, thereby activating and subsequently phosphorylating protein kinase C-delta (PKCδ); this leads to increased PKCδ-dependent activation of the NFκB pathway, followed by increased IL-1β production [25]. Knockout of TLR2 reduces the uptake of α-synuclein in mouse microglia [26]. The activation of the TLR-4–NFκB pathway mediates the incorporation of α-synuclein into autophagosomes [27,28][27][28]. A functional block of TLR4 in BV2 mouse microglia or TLR4-knockout primary mouse microglia inhibits the uptake of α-synuclein and prevents TNF-α and IL-6 production [29]. α-Synuclein also increases the microglial expression of IFN-γ, thereby inducing neuronal MHC-I expression; thus, the neurons can be selectively targeted by CD8+ T cells [30]. α-Synuclein is encoded by SNCA. SNCA overexpression in rat SN decreases fiber density in DAergic neurons and increases the number of MHC-II+ microglial cells [31]. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice, T cells from mice immunized to nitrated α-synuclein potentiate neurodegeneration in response to MPTP [22]. Both proinflammatory type 1 T helper (Th1) and type 17 T helper (Th17) subtypes can enhance MPTP-induced neurodegeneration, whereas the regulator T cell (Treg) subtype is protective against it [32]. These results support the role of T cell subsets activated by α-synuclein-induced immune responses in the pathogenesis of DAergic neurodegeneration. Humoral adaptive immunity is also involved in PD pathogenesis. Numerous autoantibodies target CNS-specific proteins, such as tau, S100B, glial fibrillar acidic protein (GFAP) [33[33][34][35],34,35], neurofilament [36[36][37],37], GM1 [38], and neuronal calcium channels [39]; moreover, autoantibodies to α-synuclein [40,41][40][41] have also been discovered. Blood levels of anti-melanin antibody are elevated in the early stages of PD [42]. Together, these findings indicate that both innate and adaptive immune systems are activated in PD. In addition to the brain, α-synuclein aggregation has also been discovered in the enteric nervous system (ENS) [43]. The expression of α-synuclein in enteric neurites is positively correlated with the degree of intestinal wall inflammation [44,45][44][45]. The expression of TNF-α, IFN-γ, IL-6, and IL-1β is upregulated in colon biopsy samples of patients with PD [46]. IL-1 and IL-8 are also elevated in stool specimens of patients with PD [47]. Altered gut metabolites and microbiomes are also involved in intestinal inflammation in patients with PD [48,49,50][48][49][50]. Notably, specific gut metabolites may increase neurodegeneration in PD. In SNCA transgenic mice, short-chain fatty acids produced by the intestinal microbiome lead to a higher degree of α-synuclein aggregation in the basal ganglia and SN, potentiating motor deficits [47]. Fecal microbiota transplantation in 11 PD patients with constipation increased the abundance of Blautia and Prevotella in feces and improved motor and nonmotor symptoms [51]. Therefore, PD pathogenesis likely involves an interplay among gut microbiota, metabolites, and cytokines.

3. Candidate Biomarkers of Inflammation in PDs

The clinical diagnosis of PD is made mostly based on clinical symptoms, which may appear only in advanced disease stages, thus precluding therapeutic intervention in early stages. Biomarkers are important for detecting PD in the early stage as well as for monitoring disease progression and treatment responses. Among molecular biomarkers of PD, α-synuclein, tau, and Aβ42 in the CSF, blood, and other body fluids have attracted considerable research interest [10,52,53,54,55,56,57][10][52][53][54][55][56][57]. Inflammatory molecules can be used as potential biomarkers to reflect the neuroinflammatory pathogenesis of PD [10,15,58][10][15][58]. Because obtaining live human neurons from patients with PD is challenging, the CSF is an acceptable source and can be used to detect molecular changes underlying the neurodegenerative pathogenesis. The leakage of inflammatory factors from degenerated brain regions can also be detected in the peripheral blood. The alterations of inflammatory biomarkers in the blood of patients with PD also indicate the peripheral involvement of PD pathogenesis, such as the gut–brain axis. Recent studies have described IL-1β, IL-2, IL-6, IL-10, high-sensitivity C-reactive protein (hsCRP), TNF-α/soluble TNF-receptors (sTNFRs), and regulated upon activation, normal T cell expressed and presumably secreted (RANTES), as potential peripheral biomarkers (Table 1).

3.1. IL-1β

IL-1β is a proinflammatory cytokine with pleiotropic biological actions in the peripheral blood and brain. Sustained IL-1β expression in the striatum causes DAergic neuronal death and motor disabilities in rats [59]. IL-1β levels are elevated in the striatum of patients with PD [60,61][60][61]. IL-1β levels in the CSF are elevated in patients with PD, particularly those with probable REM sleep behavior disorder (PRBD) [62]. Serum IL-1β levels are significantly elevated in patients with PD, and those who also exhibit high titers of antibodies against common pathogens [63,64][63][64]. A large multicenter study demonstrated higher serum IL-1β levels in patients with PD compared with control participants [11]. However, other studies did not observe alterations in IL-1β levels in the serum [65] and CSF [66] samples of patients with PD. A 2016 meta-analysis including six studies (623 patients) concluded that blood IL-1β levels are elevated in patients with PD [15].

3.2. IL-2

The gut microbiome composition may alter cytokine profiles and affect inflammatory processes in PD [67], whereas IL-2 can suppress chronic inflammation in the gastrointestinal tract [68,69,70][68][69][70]. IL-2 plays a critical role in T cell proliferation, Treg cell expansion, and mediation of inflammation-induced cell death [71]. Decreased blood IL-2 levels reduce the number and function of Treg cells, leading to lymphoproliferation and autoimmunity [71]. IL-2 levels are elevated in the striatum of patients with PD [72]. Patients with PD have higher serum IL-2 levels than control participants [11,73,74][11][73][74]; the higher serum IL-2 levels can be reduced by treatment with antiparkinsonian medications [74]. In addition, high serum levels of soluble IL-2 receptors (sIL-2R) are associated with severe symptoms of anxiety or depression in patients with PD [75]. The meta-analysis in 2016 including three studies (282 patients) revealed the elevation of IL-2 in the blood of patients with PD [15].

3.3. IL-6

IL-6 is a multifunctional cytokine mainly secreted by neurons and glial cells, and it plays a vital role in neuronal development and differentiation [76]. It triggers neuronal survival after injury but also causes neuronal death in neurodegenerative diseases [77]. IL-6 levels are elevated in the striatum, CSF, and serum of patients with PD [64,73,75,78,79,80,81,82,83][64][73][75][78][79][80][81][82][83]. Higher serum IL-6 levels are correlated with infection in patients with PD [63]. Serum IL-6 levels are inversely correlated with clinical parameters, including functional mobility, gait speed, and Mini-Mental Status Examination scores, in patients with PD [84,85][84][85]. Scalzo et al. reported that serum IL-6 levels cannot reflect PD severity because serum IL-6 levels were not correlated with the scores of Unified Parkinson’s Disease Rating Scale (UPDRS) part III and H&Y stage [84]. However, regarding the nonmotor symptoms of PD evaluated using UPDRS part I, plasma IL-6 levels were correlated with the severity of depression [85]. Another study reported no correlation of serum IL-6 levels with H&Y stages, disease duration, and UPDRS scores [81]. Elevated serum IL-6 levels are also associated with death in patients with PD [86]. The scores of the activity daily living scale in patients with PD are negatively correlated with serum IL-6 levels [13]. However, some studies have not detected an elevation of serum IL-6 levels in patients with PD [11[11][64][66][74],64,66,74], although a 2016 meta-analysis including 13 studies (898 patients) revealed higher peripheral IL-6 levels in patients with PD [15].

3.4. IL-10

IL-10 is an anti-inflammatory cytokine produced by lymphocytes and microglia [87]. It has neuroprotective effects against LPS-induced cell death [88]. Serum IL-10 levels are increased in patients with PD compared with control participants [11,73,89][11][73][89]. However, two studies have not indicated any changes in serum and CSF IL-10 levels in patients with PD [66[66][90],90], whereas the meta-analysis in 2016 including five studies (376 patients) demonstrated higher peripheral IL-10 levels in patients with PD [15].

3.5. TNF-α/sTNFRs

TNF-α is a proinflammatory cytokine that plays a key role in host defense [91]. TNF-α binds to sTNFR and regulates sTNFR expression; sTNFR expression may be an indicator of TNF-α activity [92]. TNF-α activates microglia to induce the progressive loss of DAergic neurons in the SN [93,94,95][93][94][95]. TNF-α is upregulated in the SN of patients with PD [96]. TNF-α levels in the CSF are elevated in PD patients [94], particularly those with PRBD [62]. Serum TNF-α levels are also elevated in patients with PD [11,66,73,75,82,83][11][66][73][75][82][83] and those with atypical parkinsonism [73]. Elevated plasma sTNFR1 is associated with poor executive function in patients with PD [97]. Plasma TNF-α levels are positively correlated with cognitive impairment, depression, and disability in patients with PD [75,98][75][98]. Serum TNF-α levels are not significantly elevated in PD patients with infectious burdens [63]. The meta-analysis in 2016 including nine studies (809 patients) demonstrated higher peripheral TNF-α levels in patients with PD [15].

3.6. RANTES

RANTES is a proinflammatory chemokine involved in the regulation of immunoreactions and the recruitment of immune cells such as monocytes, granulocytes, and T cells to sites of inflammation [99]. A study reported that serum RANTES levels in patients with PD were higher than those in control participants [100]. Serum RANTES levels are positively correlated with H&Y stages and disease duration [82[82][101],101], but are not associated with UPDRS scores [82]. However, Gangemi et al. noted that serum RANTES levels were comparable in patients with PD and control participants [102], whereas the meta-analysis in 2016 including five studies (171 patients) demonstrated higher blood RANTES levels in patients with PD [15].

3.7. High-Sensitivity C-Reactive Protein (hsCRP)

The circulating hsCRP level is a useful marker of ongoing inflammation or tissue damage [103]. hsCRP has potential as a marker of neuroinflammation in PD [104]. Elevated plasma hsCRP levels are present in patients with PD who underwent levodopa treatment [105]. Serum hsCRP levels are also higher in patients with PD than in control participants [106,107][106][107]. However, these elevations of hsCRP have not been recapitulated by other studies [11,75,108][11][75][108]. The meta-analysis in 2016 including six studies (696 patients) demonstrated higher blood hsCRP levels in patients with PD [15].

References

  1. Braak, H.; Del Tredici, K.; Rüb, U.; de Vos, R.A.; Jansen Steur, E.N.H.; Braak, E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging 2003, 24, 197–211.
  2. Domingo, A.; Klein, C. Genetics of Parkinson disease. Handb. Clin. Neurol. 2018, 147, 211–227.
  3. Kim, C.Y.; Alcalay, R.N. Genetic forms of Parkinson’s disease. Semin Neurol. 2017, 37, 135–146.
  4. Ascherio, A.; Schwarzschild, M.A. The epidemiology of Parkinson’s disease: Risk factors and prevention. Lancet Neurol. 2016, 15, 1257–1272.
  5. De Virgilio, A.; Greco, A.; Fabbrini, G.; Inghilleri, M.; Rizzo, M.I.; Gallo, A.; Conte, M.; Rosato, C.; Appiani, M.C.; de Vincentiis, M. Parkinson’s disease: Autoimmunity and neuroinflammation. Autoimmun. Rev. 2016, 15, 1005–1011.
  6. McGeer, P.L.; Itagaki, S.; Boyes, B.E.; McGeer, E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 1988, 38, 1285–1291.
  7. Gerhard, A.; Pavese, N.; Hotton, G.; Turkheimer, F.; Es, M.; Hammers, A.; Eggert, K.; Oertel, W.; Banati, R.B.; Brooks, D.J. In vivo imaging of microglial activation with (R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol. Dis. 2006, 21, 404–412.
  8. Theodore, S.; Cao, S.; McLean, P.J.; Standaert, D.G. Targeted overexpression of human α-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J. Neuropathol. Exp. Neurol. 2008, 67, 1149–1158.
  9. Hong, Z.; Shi, M.; Chung, K.A.; Quinn, J.F.; Peskind, E.R.; Galasko, D.; Jankovic, J.; Zabetian, C.P.; Leverenz, J.B.; Baird, G.; et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain 2010, 133, 713–726.
  10. Parnetti, L.; Castrioto, A.; Chiasserini, D.; Persichetti, E.; Tambasco, N.; El-Agnaf, O.; Calabresi, P. Cerebrospinal fluid biomarkers in Parkinson disease. Nat. Rev. Neurol. 2013, 9, 131–140.
  11. Williams-Gray, C.H.; Wijeyekoon, R.; Yarnall, A.J.; Lawson, R.A.; Breen, D.P.; Evans, J.R.; Cummins, G.A.; Duncan, G.W.; Khoo, T.K.; Burn, D.J.; et al. ICICLE-PD study group. Serum immune markers and disease progression in an incident Parkinson’s disease cohort (ICICLE-PD). Mov. Disord. 2016, 31, 995–1003.
  12. Nagatsu, T.; Mogi, M.; Ichinose, H.; Togari, A. Changes in cytokines and neurotrophins in Parkinson’s disease. J. Neural. Transm. Suppl. 2000, 60, 277–290.
  13. Hofmann, K.W.; Schuh, A.F.; Saute, J.; Townsend, R.; Fricke, D.; Leke, R.; Souza, D.O.; Portela, L.V.; Chaves, M.L.; Rieder, C.R. Interleukin-6 serum levels in patients with Parkinson’s disease. Neurochem. Res. 2009, 34, 1401–1404.
  14. Scalzo, P.; Kummer, A.; Cardoso, F.; Teixeira, A.L. Increased serum levels of soluble tumor necrosis factor-alpha receptor-1 in patients with Parkinson’s disease. J. Neuroimmunol. 2009, 216, 122–125.
  15. Qin, X.Y.; Zhang, S.P.; Cao, C.; Loh, Y.P.; Cheng, Y. Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: A systematic review and meta-analysis. JAMA Neurol. 2016, 73, 1316–1324.
  16. Ezcurra, A.L.d.L.; Chertoff, M.; Ferrari, C.; Graciarena, M.; Pitossi, F. Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation. Neurobiol. Dis. 2010, 37, 630–640.
  17. Imamura, K.; Hishikawa, N.; Sawada, M.; Nagatsu, T.; Yoshida, M.; Hashizume, Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson’s disease brains. Acta Neuropathol. 2003, 106, 518–526.
  18. Loane, C.; Politis, M. Positron emission tomography neuroimaging in Parkinson’s disease. Am. J. Transl. Res. 2011, 3, 323–341.
  19. Papadopoulos, V.; Baraldi, M.; Guilarte, T.R.; Knudsen, T.B.; Lacapere, J.J.; Lindemann, P.; Norenberg, M.D.; Nutt, D.; Weizman, A.; Zhang, M.R.; et al. Translocator protein (18kDa): New nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol. Sci. 2006, 27, 402–409.
  20. Bennett, M.C. The role of alpha-synuclein in neurodegenerative diseases. Pharmacol. Ther. 2005, 105, 311–331.
  21. Béraud, D.; Maguire-Zeiss, K.A. Misfolded α-synuclein and toll-like receptors: Therapeutic targets for Parkinson’s disease. Parkinsonism Relat. Disord. 2012, 18, S17–S20.
  22. Reynolds, A.D.; Glanzer, J.G.; Kadiu, I.; Ricardo-Dukelow, M.; Chaudhuri, A.; Ciborowski, P.; Cerny, R.; Gelman, B.; Thomas, M.P.; Mosley, R.L.; et al. Nitrated alpha-synuclein-activated microglial profiling for Parkinson’s disease. J. Neurochem. 2008, 104, 1504–1525.
  23. Lee, E.J.; Woo, M.S.; Moon, P.G.; Baek, M.C.; Choi, I.Y.; Kim, W.K.; Junn, E.; Kim, H.S. Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J. Immunol. 2010, 185, 615–623.
  24. Couch, Y.; Alvarez-Erviti, L.; Sibson, N.R.; Wood, M.J.; Anthony, D.C. The acute inflammatory response to intranigral α-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation. J. Neuroinflammation 2011, 8, 166.
  25. Panicker, N.; Sarkar, S.; Harischandra, D.S.; Neal, M.; Kam, T.I.; Jin, H.; Saminathan, H.; Langley, M.; Charli, A.; Samidurai, M.; et al. Fyn kinase regulates misfolded α-synuclein uptake and NLRP3 inflammasome activation in microglia. J. Exp. Med. 2019, 216, 1411–1430.
  26. Kim, C.; Ho, D.H.; Suk, J.E.; You, S.; Michael, S.; Kang, J.; Joong Lee, S.; Masliah, E.; Hwang, D.; Lee, H.J.; et al. Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat. Commun. 2013, 4, 1562.
  27. Choi, I.; Zhang, Y.; Seegobin, S.P.; Pruvost, M.; Wang, Q.; Purtell, K.; Zhang, B.; Yue, Z. Microglia clear neuron-released alpha-synuclein via selective autophagy and prevent neurodegeneration. Nat. Commun. 2020, 11, 1386.
  28. Choi, I.; Seegobin, S.P.; Liang, D.; Yue, Z. Synucleinphagy: A microglial “community cleanup program” for neuroprotection. Autophagy 2020, 16, 1718–1720.
  29. Fellner, L.; Irschick, R.; Schanda, K.; Reindl, M.; Klimaschewski, L.; Poewe, W.; Wenning, G.K.; Stefanova, N. Toll-like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia. Glia 2013, 61, 349–360.
  30. Cebrián, C.; Zucca, F.A.; Mauri, P.; Steinbeck, J.A.; Studer, L.; Scherzer, C.R.; Kanter, E.; Budhu, S.; Mandelbaum, J.; Vonsattel, J.P.; et al. MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. Nat. Commun. 2014, 5, 3633.
  31. Sanchez-Guajardo, V.; Febbraro, F.; Kirik, D.; Romero-Ramos, M. Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson’s disease. PLoS ONE 2010, 5, e8784.
  32. Reynolds, A.D.; Stone, D.K.; Hutter, J.A.; Benner, E.J.; Mosley, R.L.; Gendelman, H.E. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson’s disease. J. Immunol. 2010, 184, 2261–2271.
  33. Terryberry, J.W.; Thor, G.; Peter, J.B. Autoantibodies in neurodegenerative diseases- antigen-specific frequencies and intrathecal analysis. Neurobiol. Aging 1998, 19, 205–216.
  34. Poletaev, A.B.; Morozov, S.G.; Gnedenko, B.B.; Zlunikin, V.M.; Korzhenevskey, D.A. Serum anti-S100b, anti-GFAP and anti-NGF autoantibodies of IgG class in healthy persons and patients with mental and neurological disorders. Autoimmunity 2000, 32, 33–38.
  35. Gruden, M.A.; Sewell, R.D.; Yanamandra, K.; Davidova, T.V.; Kucheryanu, V.G.; Bocharov, E.V.; Bocharova, O.A.; Polyschuk, V.V.; Sherstnev, V.V.; Morozova-Roche, L.A. Immunoprotection against toxic biomarkers is retained during Parkinson’s disease progression. J. Neuroimmunol. 2011, 233, 221–227.
  36. Karcher, D.; Federsppiel, B.S.; Lowenthal, F.D.; Frank, F.; Lowenthal, A. Anti-neurofilament antibodies in blood of patients with neurological diseases. Acta Neuropathol. 1986, 72, 82–85.
  37. Elizan, T.S.; Casals, J.; Yahr, M.D. Antineurofilament antibodies in postencephalitic and idiopathic Parkinson’s disease. J. Neurol. Sci. 1983, 59, 341–347.
  38. Zappia, M.; Crescibene, L.; Bosco, D.; Arabia, G.; Nicoletti, G.; Bagala, A.; Bastone, L.; Napoli, I.D.; Caracciolo, M.; Bonavita, S.; et al. Anti-GM1 ganglioside antibodies in Parkinson’s disease. Acta Neurol. Scand. 2002, 106, 54–57.
  39. Appel, S.H.; Smith, R.G.; Alexianu, M.; Engelhardt, J.; Mosier, D.; Colom, L.; Stefani, E. Neurodegenerative disease: Autoimmunity involving calcium channels. Ann. NY Acad Sci. 1994, 747, 183–194.
  40. Yanamandra, K.; Gruden, M.A.; Casaite, V.; Meskys, R.; Forsgren, L.; Morozova-Roche, L.A. Alpha-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson’s disease patients. PLoS ONE 2011, 6, e18513.
  41. Papachroni, K.K.; Ninkina, N.; Papapanagiotou, A.; Hadjigeorgiou, G.M.; Xiromerisiou, G.; Papadimitriou, A.; Kalofoutis, A.; Buchman, V.L. Autoantibodies to alpha-synuclein in inherited Parkinson’s disease. J. Neurochem. 2007, 101, 749–756.
  42. Double, K.L.; Rowe, D.B.; Carew-Jones, F.M.; Hayes, M.; Chan, D.K.; Blackie, J.; Corbett, A.; Joffe, R.; Fung, V.S.; Morris, J.; et al. Anti-melanin antibodies are increased in sera in Parkinson’s disease. Exp. Neurol. 2009, 217, 297–301.
  43. Goedert, M.; Spillantini, M.G.; Del Tredici, K.; Braak, H. 100 years of Lewy pathology. Nat. Rev. Neurol. 2013, 9, 13–24.
  44. Sampson, T.R.; Debelius, J.W.; Thron, T.; Janssen, S.; Shastri, G.G.; Ilhan, Z.E.; Challis, C.; Schretter, C.E.; Rocha, S.; Gradinaru, V.; et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell 2016, 167, 1469–1480.e12.
  45. Stolzenberg, E.; Berry, D.; Yang, D.; Lee, E.Y.; Kroemer, A.; Kaufman, S.; Wong, G.C.L.; Oppenheim, J.J.; Sen, S.; Fishbein, T.; et al. A role for neuronal alpha-synuclein in gastrointestinal immunity. J. Innate Immun. 2017, 9, 456–463.
  46. Houser, M.C.; Chang, J.; Factor, S.A.; Molho, E.S.; Zabetian, C.P.; Hill-Burns, E.M.; Payami, H.; Hertzberg, V.S.; Tansey, M.G. Stool immune profiles evince gastrointestinal inflammation in Parkinson’s disease. Mov. Disord. 2018, 33, 793–804.
  47. Challis, C.; Hori, A.; Sampson, T.R.; Yoo, B.B.; Challis, R.C.; Hamilton, A.M.; Mazmanian, S.K.; Volpicelli-Daley, L.A.; Gradinaru, V. Gut-seeded alpha-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice. Nat. Neurosci. 2020, 23, 327–336.
  48. Hasegawa, S.; Goto, S.; Tsuji, H.; Okuno, T.; Asahara, T.; Nomoto, K.; Shibata, A.; Fujisawa, Y.; Minato, T.; Okamoto, A.; et al. Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson’s disease. PLoS ONE 2015, 10, e0142164.
  49. Keshavarzian, A.; Green, S.J.; Engen, P.A.; Voigt, R.M.; Naqib, A.; Forsyth, C.B.; Mutlu, E.; Shannon, K.M. Colonic bacterial composition in Parkinson’s disease. Mov. Disord. 2015, 30, 1351–1360.
  50. Unger, M.M.; Spiegel, J.; Dillmann, K.U.; Grundmann, D.; Philippeit, H.; Burmann, J.; Fassbender, K.; Schwiertz, A.; Schafer, K.H. Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. Parkinsonism Relat. Disord. 2016, 32, 66–72.
  51. Kuai, X.Y.; Yao, X.H.; Xu, L.J.; Zhou, Y.Q.; Zhang, L.P.; Liu, Y.; Pei, S.F.; Zhou, C.L. Evaluation of fecal microbiota transplantation in Parkinson’s disease patients with constipation. Microb. Cell Fact. 2021, 20, 98.
  52. Parnetti, L.; Farotti, L.; Eusebi, P.; Chiasserini, D.; De Carlo, C.; Giannandrea, D.; Salvadori, N.; Lisetti, V.; Tambasco, N.; Rossi, A.; et al. Al. Differential role of CSF alpha-synuclein species, tau, and Abeta42 in Parkinson’s Disease. Front. Aging Neurosci. 2014, 6, 53.
  53. Gao, L.; Tang, H.; Nie, K.; Wang, L.; Zhao, J.; Gan, R.; Huang, J.; Zhu, R.; Feng, S.; Duan, Z.; et al. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson’s disease diagnosis: A systematic review and meta-analysis. Int. J. Neurosci. 2015, 125, 645–654.
  54. Hall, S.; Surova, Y.; Ohrfelt, A.; Zetterberg, H.; Lindqvist, D.; Hansson, O. CSF biomarkers and clinical progression of Parkinson disease. Neurology 2015, 84, 57–63.
  55. Eusebi, P.; Giannandrea, D.; Biscetti, L.; Abraha, I.; Chiasserini, D.; Orso, M.; Calabresi, P.; Parnetti, L. Diagnostic utility of cerebrospinal fluid alpha-synuclein in Parkinson’s disease: A systematic review and meta-analysis. Mov. Disord. 2017, 32, 1389–1400.
  56. Mollenhauer, B.; Caspell-Garcia, C.J.; Coffey, C.S.; Taylor, P.; Shaw, L.M.; Trojanowski, J.Q.; Singleton, A.; Frasier, M.; Marek, K.; Galasko, D. Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. Neurology 2017, 89, 1959–1969.
  57. Sako, W.; Murakami, N.; Izumi, Y.; Kaji, R. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: Evidence from a meta-analysis. Mov. Disord. 2014, 29, 1599–1605.
  58. Reale, M.; Iarlori, C.; Thomas, A.; Gambi, D.; Perfetti, B.; Di Nicola, M.; Onofrj, M. Peripheral cytokines profile in Parkinson’s disease. Brain Behav. 2009, 23, 55–63.
  59. Ferrari, C.C.; Pott Godoy, M.C.; Tarelli, R.; Chertoff, M.; Depino, A.M.; Pitossi, F.J. Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra. Neurobiol. Dis. 2006, 24, 183–193.
  60. Mogi, M.; Harada, M.; Narabayashi, H.; Inagaki, H.; Minami, M.; Nagatsu, T. Interleukin (IL)-lβ, IL-2, IL-4, IL-6 and transforming growth factor-a levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson’s disease. Neurosci. Lett. 1996, 211, 13–16.
  61. Nagatsu, T.; Mogi, M.; Ichinose, H.; Togari, A. Cytokines in Parkinson’s disease. J. Neural. Transm. Suppl. 2000, 10, 143–151.
  62. Hu, Y.; Yu, S.Y.; LJ, Z.; Cao, C.J.; Wang, F.; Chen, Z.J.; Du, Y.; Lian, T.H.; Wang, Y.J.; Chan, P.; et al. Parkinson disease with REM sleep behavior disorder: Features, α-synuclein, and inflammation. Neurology 2015, 84, 888–894.
  63. Bu, X.L.; Wang, X.; Xiang, Y.; Shen, L.L.; Wang, Q.H.; Liu, Y.H.; Jiao, S.S.; Wang, Y.R.; Cao, H.Y.; Yi, X.; et al. The association between infectious burden and Parkinson’s disease: A case-control study. Parkinsonism Relat. Disord. 2015, 21, 877–881.
  64. Dursun, E.; Gezen-Ak, D.; Hanagasi, H.; Bilgic, B.; Lohmann, E.; Ertan, S.; Atasoy, I.L.; Alaylioglu, M.; Araz, O.S.; Onal, B.; et al. The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer’s disease, mild cognitive impairment or Parkinson’s disease. J. Neuroimmunol. 2015, 283, 50–57.
  65. Pirttila, T.; Mehta, P.D.; Frey, H.; Wisniewski, H.M. Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer’s disease. Neurobiol. Aging 1994, 15, 313–317.
  66. Koziorowski, D.; Tomasiuk, R.; Szlufik, S.; Friedman, A. Inflammatory cytokines and NT-proCNP in Parkinson’s disease patients. Cytokine 2012, 60, 762–766.
  67. Lin, C.H.; Chen, C.C.; Chiang, H.L.; Liou, J.M.; Chang, C.M.; Lu, T.P.; Chuang, E.Y.; Tai, Y.C.; Cheng, C.; Lin, H.Y.; et al. Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson’s disease. J. Neuroinflammation 2019, 16, 129.
  68. Malek, T.R. The biology of interleukin-2. Annu Rev. Immunol. 2008, 26, 453–479.
  69. Boyman, O.; Sprent, J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 2012, 12, 180–190.
  70. Sadlack, B.; Merz, H.; Schorle, H.; Schimpl, A.; Feller, A.C.; Horak, I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993, 75, 253–261.
  71. Rochman, Y.; Spolski, R.; Leonard, W.J. New insights into the regulation of t cells by gamma(c) family cytokines. Nat. Rev. Immunol. 2009, 9, 480–490.
  72. Mogi, M.; Harada, M.; Kondo, T.; Riederer, P.; Nagatsu, T. Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain. Short communication. J. Neural. Transm. 1996, 103, 1077–1081.
  73. Brodacki, B.; Staszewski, J.; Toczylowska, B.; Kozlowska, E.; Drela, N.; Chalimoniuk, M.; Stepien, A. Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci. Lett. 2008, 441, 158–162.
  74. Stypuła, G.; Kunert-Radek, J.; Stepień, H.; Zylińska, K.; Pawlikowski, M. Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with parkinson’s disease. Neuroimmunomodulation 1996, 3, 131–134.
  75. Lindqvist, D.; Kaufman, E.; Brundin, L.; Hall, S.; Surova, Y.; Hansson, O. Non-motor symptoms in patients with Parkinson’s disease—Correlations with inflammatory cytokines in serum. PLoS ONE 2012, 7, e47387.
  76. Erta, M.; Quintana, A.; Hidalgo, J. Interleukin-6, a major cytokine in the central nervous system. Int. J. Biol. Sci. 2012, 8, 1254–1266.
  77. Gruol, D.L.; Nelson, T.E. Physiological and pathological roles of interleukin-6 in the central nervous system. Mol. Neurobiol. 1997, 15, 307–339.
  78. Miiller, T.; Blum-Degen, D.; Przuntek, H.; Kuhn, W. Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson’s disease. Acta Neurol. Scand. 1998, 98, 142–144.
  79. Mogi, M.; Harada, M.; Kondo, T.; Riederer, P.; Inagaki, H.; Minami, M.; Nagatsu, T. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett. 1994, 180, 147–150.
  80. Blum-Degen, D.; Müller, T.; Kuhn, W.; Gerlach, M.; Przuntek, H.; Riederer, P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer’s and de novo Parkinson’s disease patients. Neurosci. Lett. 1995, 202, 17–20.
  81. Tang, P.; Chong, L.; Li, X.; Liu, Y.; Liu, P.; Hou, C.; Li, R. Correlation between serum RANTES levels and the severity of Parkinson’s disease. Oxid. Med. Cell Longev. 2014, 2014, 208408.
  82. Gruden, M.A.; Yanamandra, K.; Kucheryanu, V.G.; Bocharova, O.R.; Sherstnev, V.V.; Morozova-Roche, L.A.; Sewell, R.D. Correlation between protective immunity to α-synuclein aggregates, oxidative stress and inflammation. Neuroimmunomodulation 2012, 19, 334–342.
  83. Dobbs, R.J.; Charlett, A.; Purkiss, A.G.; Dobbs, S.M.; Weller, C.; Peterson, D.W. Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol. Scand. 1999, 100, 34–41.
  84. Scalzo, P.; Kummer, A.; Cardoso, F.; Teixeira, A.L. Serum levels of interleukin-6 are elevated in patients with Parkinson’s disease and correlate with physical performance. Neurosci. Lett. 2010, 468, 56–58.
  85. Selikhova, M.V.; Kushlinskii, N.E.; Lyubimova, N.V.; Gusev, E.I. Impaired production of plasma interleukin-6 in patients with Parkinson’s disease. Bull. Exp. Biol Med. 2002, 133, 81–83.
  86. Dufek, M.; Rektorova, I.; Thon, V.; Lokaj, J.; Rektor, I. Interleukin-6 may contribute to mortality in Parkinson’s disease patients: A 4-Year prospective study. Parkinsons Dis. 2015, 2015, 898192.
  87. Moore, K.W.; O’Garra, A.; de Waal Malefyt, R.; Vieira, P.; Mosmann, T.R. Interleukin-10. Annu Rev. Immunol. 1993, 11, 165–190.
  88. Molina-Holgado, F.; Grencis, R.; Rothwell, N.J. Actions of exogenous and endogenous IL-10 on glial responses to bacterial LPS/cytokines. Glia 2001, 33, 97–106.
  89. Rentzos, M.; Nikolaou, C.; Andreadou, E.; Paraskevas, G.P.; Rombos, A.; Zoga, M.; Tsoutsou, A.; Boufidou, F.; Kapaki, E.; Vassilopoulos, D. Circulating interleukin-10 and interleukin-12 in Parkinson’s disease. Acta Neurol. Scand. 2009, 119, 332–337.
  90. Rota, E.; Bellone, G.; Rocca, P.; Bergamasco, B.; Emanuelli, G.; Ferrero, P. Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer’s disease patients. Neurol. Sci. 2006, 27, 33–39.
  91. Tracey, K.J.; Cerami, A. Tumor necrosis factor: A pleiotropic cytokine and therapeutic target. Annu Rev. Med. 1994, 45, 491–503.
  92. Aderka, D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev. 1996, 7, 231–240.
  93. Qin, L.; Wu, X.; Block, M.L.; Liu, Y.; Breese, G.R.; Hong, J.S.; Knapp, D.J.; Crews, F.T. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007, 55, 453–462.
  94. Mogi, M.; Harada, M.; Riederer, P.; Narabayashi, H.; Fujita, K.; Nagatsu, T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 1994, 165, 208–210.
  95. Teismann, P.; Tieu, K.; Cohen, O.; Choi, D.K.; Wu, D.C.; Marks, D.; Vila, M.; Jackson-Lewis, V.; Przedborski, S. Pathogenic role of glial cells in Parkinson’s disease. Mov. Disord. 2003, 18, 121–129.
  96. Boka, G.; Anglade, P.; Wallach, D.; Javoy-Agid, F.; Agid, Y.; Hirsch, E.C. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson’s disease. Neurosci. Lett. 1994, 172, 151–154.
  97. Rocha, N.P.; Teixeira, A.L.; Scalzo, P.L.; Barbosa, I.G.; de Sousa, M.S.; Morato, I.B.; Vieira, E.L.; Christo, P.P.; Palotas, A.; Reis, H.J. Plasma levels of soluble tumor necrosis factor receptors are associated with cognitive performance in Parkinson’s disease. Mov. Disord. 2014, 29, 527–531.
  98. Menza, M.; Dobkin, R.D.; Marin, H.; Mark, M.H.; Gara, M.; Bienfait, K.; Dicke, A.; Kusnekov, A. The role of inflammatory cytokines in cognition and oTher. non-motor symptoms of Parkinson’s disease. Psychosomatics 2010, 51, 474–479.
  99. Appay, V.; Rowland-Jones, S.L. RANTES: A versatile and controversial chemokine. Trends Immunol. 2001, 22, 83–87.
  100. Mahlknecht, P.; Stemberger, S.; Sprenger, F.; Rainer, J.; Hametner, E.; Kirchmair, R.; Grabmer, C.; Scherfler, C.; Wenning, G.K.; Seppi, K.; et al. An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes. Proteome Sci. 2012, 10, 71.
  101. Rentzos, M.; Nikolaou, C.; Andreadou, E.; Paraskevas, G.P.; Rombos, A.; Zoga, M.; Tsoutsou, A.; Boufidou, F.; Kapaki, E.; Vassilopoulos, D. Circulating interleukin-15 and RANTES chemokine in Parkinson’s disease. Acta Neurol. Scand. 2007, 116, 374–937.
  102. Gangemi, S.; Basile, G.; Merendino, R.A.; Epifanio, A.; Di Pasquale, G.; Ferlazzo, B.; Nicita-Mauro, V.; Morgante, L. Effect of levodopa on interleukin-15 and RANTES circulating levels in patients affected by Parkinson’s disease. Mediat. Inflamm. 2003, 12, 251–253.
  103. Palasik, W.; Fiszer, U.; Lechowicz, W.; Czartoryska, B.; Krzesiewicz, M.; Lugowska, A. Assessment of relations between clinical outcome of ischemic stroke and activity of inflammatory processes in the acute phase based on examination of selected parameters. Eur. Neurol. 2005, 53, 188–193.
  104. Song, I.U.; Chung, S.W.; Kim, J.S.; Lee, K.S. Association between high-sensitivity C-reactive protein and risk of early idiopathic Parkinson’s disease. Neurol. Sci. 2011, 32, 31–34.
  105. Andican, G.; Konukoglu, D.; Bozluolcay, M.; Bayulkem, K.; Firtiina, S.; Burcak, G. Plasma oxidative and inflammatory markers in patients with idiopathic Parkinson’s disease. Acta Neurol. Belg. 2012, 112, 155–159.
  106. Akil, E.; Bulut, A.; Kaplan, I.; Ozdemir, H.H.; Arslan, D.; Aluclu, M.U. The increase of carcinoembryonic antigen (CEA), high-sensitivity C-reactive protein, and neutrophil/lymphocyte ratio in Parkinson’s disease. Neurol. Sci. 2015, 36, 423–428.
  107. Song, I.U.; Kim, Y.D.; Cho, H.J.; Chung, S.W. Is neuroinflammation involved in the development of dementia in patients with Parkinson’s disease? Intern. Med. 2013, 52, 1787–1792.
  108. Song, I.U.; Kim, J.S.; Chung, S.W.; Lee, K.S. Is there an association between the level of high-sensitivity C-reactive protein and idiopathic Parkinson’s disease? A comparison of Parkinson’s disease patients, disease controls and healthy individuals. Eur Neurol. 2009, 62, 99–104.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Video Production Service
Feedback